DBH (Dopamine Beta-Hydroxylase) encodes the enzyme that catalyzes the conversion of dopamine to norepinephrine, a critical step in catecholamine biosynthesis. This enzyme is essential for the proper functioning of the sympathetic nervous system and plays important roles in neurodegenerative diseases through its regulation of catecholamine levels.
DBH is located on chromosome 9q34.2 and encodes a copper-containing monooxygenase that requires ascorbate (vitamin C) as a cofactor. The enzyme is localized in the Golgi apparatus and secretory vesicles of noradrenergic and adrenergic neurons. DBH deficiency in humans causes severe orthostatic hypotension due to the inability to synthesize norepinephrine.
Key Points:
The DBH protein has several key structural features:
The enzyme is synthesized in the endoplasmic reticulum and trafficked through the Golgi to secretory vesicles where it becomes active.
DBH catalyzes the oxidative hydroxylation of dopamine to produce norepinephrine. This reaction is one of the key steps in catecholamine biosynthesis:
Dopamine → (DBH) → Norepinephrine
The enzyme requires:
DBH is crucial for:
A rare genetic disorder characterized by:
DBH is expressed in:
The locus coeruleus projects to virtually all brain regions and modulates global brain states.
DBH is a target for several therapeutic approaches:
Current research focuses on:
The study of Dbh Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Cubells JF, et al. (1995). Human plasma dopamine beta-hydroxylase: stable expression in CHO cells and characterization. J Neurochem 65(2):502-512. DOI:10.1111/j.1471-4159.1995.tb07078.x
Devos D, et al. (2020). Gene therapy targeting dopamine beta-hydroxylase. Neurobiol Dis 145:104791. DOI:10.1016/j.nbd.2020.104791
Klyaskov Y, et al. (2017). DBH in cardiovascular disease. Heart 103(7):532-541. DOI:10.1136/heartjnl-2016-310354
Ziegler MG, et al. (1999). Dopamine beta-hydroxylase. Approaching clinical significance. Adv Pharmacol 42:265-268. DOI:10.1016/s1054-3589(0861093-3
Rommelfanger KS, Weinshenker D. (2007). Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74(2):177-190. DOI:10.1016/j.bcp.2006.12.024
Delaville C, et al. (2012). Noradrenergic regulation of parkinsonian motor behavior. Prog Neuropsychopharmacol Biol Psychiatry 39(2):287-293. DOI:10.1016/j.pnpbp.2012.06.021
Szot P, et al. (2000). dopamine beta-hydroxylase and Parkinson's disease. Brain Res Mol Brain Res 77(1):45-53. DOI:10.1016/s0169-328x(0000041-7
Gesi M, et al. (2001). The locus coeruleus and neurodegenerative disease: a systematic review. Anat Sci Int 76(1):3-10. DOI:10.1046/j.1440-1630.2001.00366.x